About 10%-20% of people with multiple sclerosis (MS) receive baclofen to control their spasticity, but up to half of patients stop the medication in the first six months, a large Swedish population-based study shows. The high rates of discontinuation suggest baclofen has “a low success rate of…
Celiac disease, in which the ingestion of gluten causes the immune system to attack the lining of the small intestine, is not common in people with multiple sclerosis (MS), a meta-analysis found. While the diet-caused autoimmune disease is estimated to affect between 0.2% and 0.7% of people in the…
Frequency Therapeutics has established a clinical advisory board, with experts across neuroscience fields, to help guide its small molecule treatment candidate for remyelination in multiple sclerosis (MS) into clinical testing. The company is planning to initiate a first trial of the molecule, designed to boost remyelination — the…
The severity of sexual dysfunction doesn’t seem to be associated with MRI measures of disease activity in multiple sclerosis (MS), but it was significantly linked with depression, anxiety, and fatigue, a small study found. The findings highlight the complex nature of sexual dysfunction in MS and “underscore the importance…
The U.S. Patent and Trademark Office will grant Trethera Corp. a new patent covering the composition and chemical structure of TRE-515, an experimental oral therapy being developed for multiple sclerosis (MS) and cancer. The patent number 11,446,307, titled “Crystalline forms of a deoxycytidine kinase inhibitor and…
The presence of self-reactive antibodies, typically seen in autoimmune diseases like scleroderma, may be common among patients with multiple sclerosis (MS). That finding from a small study indicates high levels of these antinuclear antibodies were correlated with relapse status and ongoing inflammation in MS. The study, “Antinuclear…
People with high levels of free vitamin D in circulation before the age of 20 have a lower risk of developing multiple sclerosis (MS) later in life, a new study suggests. A significantly lower risk was also observed among people who, at ages 30–39, had elevated levels of a…
While sexual problems are relatively common in women with multiple sclerosis (MS), it can still be difficult to openly discuss their experiences with their doctor. A questionnaire especially tailored for women with MS called the Sexual Dysfunction Management and Expectations Assessment in Multiple sclerosis – Female (SEA-MS-F) may…
NervGen Pharma has been cleared to enroll a second group of healthy volunteers into the multiple ascending dose portion of its Phase 1 clinical trial of NVG-291, a therapeutic candidate for multiple sclerosis (MS). The trial’s Safety Review Committee approved the second group after seeing promising safety data…
Multiple sclerosis (MS) treatments belonging to the class of sphingosine 1-phosphate (S1P) receptor modulators — such as Mayzent (siponimod) and Gilenya (fingolimod) — may be associated with a greater likelihood of skin cancer, results from a real-world study suggest. The association was the greatest for a form of…
A researcher at the University of Adelaide, in Australia, has received an AU$390,000 grant (about $280,000) to investigate how inflammatory T-cells reach the blood and brain of people with multiple sclerosis (MS). The 3-year fellowship grant was awarded to Iain Comerford, PhD, for his project, titled “Stopping T cells…
A neurology professor at the University of Pennsylvania (UPenn) has received the 2021 Barancik Prize for Innovation in MS Research for his work in understanding how the immune system causes multiple sclerosis (MS). The international $100,000 prize, administered by the National MS Society, was awarded to Amit…
Atara Biotherapeutics has partnered with Imeka to use its proprietary biomarker imaging technology in the ongoing EMBOLD Phase 2 clinical trial, which is investigating ATA188 for the treatment of progressive forms of multiple sclerosis (MS). The imaging technology will be used to determine if Atara’s ATA188…
Adults with multiple sclerosis (MS) and depression or anxiety, especially those of minority groups, are being asked to join a clinical trial assessing the benefits of eSupport Health’s online support group program, the National MS Society announced in a press release. The CONNECT study is particularly focused on Black and…
NervGen Pharma has received approval to begin testing multiple ascending doses of NVG-291, its lead therapeutic candidate for multiple sclerosis (MS) and other neurologic conditions, in a Phase 1 trial with healthy volunteers. This multiple ascending dose (MAD) part, in which participants will receive increasing doses of NVG-291…
XRHealth, a virtual reality clinic that provides treatments in patients’ homes, has integrated Tobii‘s eye-tracking technology into its platform, which will let clinicians treat patients with multiple sclerosis (MS) and other neurological conditions. “We are excited to partner with Tobii — the leader in eye tracking —…
Women with multiple sclerosis (MS) who receive high-efficacy disease-modifying therapies (DMTs) before conception have a greater risk of relapses and disability progression during pregnancy than those given moderate-efficacy or no DMTs, according to a systematic review of studies. Exclusive breastfeeding for at least two to four months, however,…
The U.S. Food and Drug Administration (FDA) has approved Lyvispah, a dissolvable granular formulation of baclofen, to treat spasticity in people with multiple sclerosis (MS). The strawberry-flavored formulation, developed by Saol Therapeutics, is particularly suitable to ease flexor spasticity, the involuntary bending of the knees and hips toward the…
Lucid-MS, a new chemical molecule being developed by FSD Pharma for the treatment of multiple sclerosis (MS), has shown the ability to restore motor function in an animal model of the disease, the company announced. After about 50 days of treatment, animals receiving Lucid-MS showed a marked decrease…
A researcher at the University of Houston has received a $100,000 grant to investigate adherence to oral disease-modifying therapies (DMTs) among people with multiple sclerosis (MS), and correlations between adherence patterns and disease outcomes over time. The one-year grant from the Agency for Healthcare Research and Quality was awarded…
A new collaboration between Arterys and Combinostics seeks to bring comprehensive artificial intelligence (AI) imaging solutions to the diagnosis and care of patients with multiple sclerosis (MS) and other neurological diseases. Under the partnership, Arterys will include Combinostics’ AI-powered cNeuro on its medical imaging cloud AI platform…
The Multiple Sclerosis Society of Canada is urging that all provinces and territories in Canada offer COVID-19 booster vaccines to at-risk populations, including people who are moderately to severely immunocompromised and multiple sclerosis (MS) patients. In letters sent earlier this month, in collaboration with 11 other health charities, the…
The number of lesions affecting the cerebellum — a brain region responsible for coordinating voluntary movements and motor skills such as balance, coordination, and posture — predicts manual dexterity getting worse in people with relapsing-remitting multiple sclerosis (RRMS), according to a retrospective analysis. The study, “Cerebellar pathology and…
Sanofi Genzyme has extended its collaboration with Koneksa to bring digital measures into its Phase 3 trials of tolebrutinib, an investigational therapy for relapsing and progressive forms of multiple sclerosis (MS). Through this joint effort, Koneksa’s digital biomarkers were applied to clinical trials of Parkinson’s…
The Scottish Medicines Consortium (SMC) has recommended that Ponvory (ponesimod) be offered through the National Health Service (NHS) Scotland to people with active, relapsing forms of multiple sclerosis (MS). The decision means that the oral therapy will be available at low or no cost to patients with clinically isolated syndrome (CIS),…
Numares has signed an exclusive licensing agreement with Oxford University Innovation to develop and commercialize a panel of biomarkers that identify disease progression in people with multiple sclerosis (MS). Specifically, the company aims to create a tool that detects early signs of conversion from relapsing remitting…
New preclinical data continues to support the potential of Cyxone’s investigational plant-derived peptide T20K for the treatment of multiple sclerosis (MS). In a collaboration with its academic partner, the Medical University of Vienna, Cyxone has shown that a combination of T20K plus an activator of the kappa…
The U.S. Patent and Trademark Office will grant Medsenic a patent covering the use of Arscimed, its investigational formulation of arsenic trioxide, for the treatment of relapsing-remitting multiple sclerosis (RRMS). Once issued, the patent will protect Arscimed’s use for this indication until 2037. This will add to the already…
Innodem Neurosciences is teaming up with Novartis Canada on a breakthrough clinical trial to evaluate if Innodem’s digital biomarker eye-tracking technology can monitor disease progression in people with multiple sclerosis (MS). The trial will test Innodem’s “easy-to-use, affordable technology,” which works using visible light, with no special infrared…
The National Institute for Health and Care Excellence (NICE) will not recommend that Ponvory (ponesimod) be added to the National Health Service (NHS) of England and Wales for people with active, relapsing forms of multiple sclerosis (MS). The provisional decision, made because Ponvory was not found to be…
Get regular updates to your inbox.